Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04342195 · ClinicalTrials.gov registry record
Acquiring Convalescent Specimens for COVID-19 Antibodies
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 15
- Enrollment target
NCT04342195 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 15 participants.
The verdict
NCT04342195 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify antibodies that have been generated by the patient to fight the COVID-19 infection. By identifying the most effective antibodies, scientists can make specific antibodies to use to prevent future coronavirus outbreaks or to treat patients with severe disease.
Interventions
- PROCEDURE Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-03-25 |
| Est. Completion | 2021-03-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04342195
The ClinicalTrials.gov registry entry for NCT04342195 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT04342195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04342195 about?
NCT04342195 is a clinical study titled "Acquiring Convalescent Specimens for COVID-19 Antibodies". Blood samples from participants who have recovered from COVID-19 infection will be obtained and studied. The goal of the research is to identify antibodies that have been generated by the patient to fight the COVID-19 infection. By identifying the most effective antibodies, scientists can make speci...
What is the current status of trial NCT04342195?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2020-03-25. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT04342195?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT04342195?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.